^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Ganglioglioma
    Drug:Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) +
    Cotellic (cobimetinib) (MEK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Pilocytic astrocytoma, PXA, ganglioglioma if BRAF V600E activation mutation... BRAF/MEK inhibitors...Dabrafenib/trametinib...Vemurafenib/cobimetinib.
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Melanoma)
    New
    Excerpt:
    COTELLIC is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    J Clin Pharm Ther
    Title:

    Combination of BRAF and MEK inhibition in BRAF V600E mutant low-grade ganglioglioma

    Excerpt:
    A 32-year-old man with an unresectable, BRAF V600E mutant, WHO grade 1 ganglioglioma is commenced on combination BRAF and MEK inhibition (vemurafenib and cobimetinib). Partial radiological and clinical response was noted after 13 weeks of treatment.
    DOI:
    10.1111/jcpt.13112